¼¼°èÀÇ ¼ÒÀ¯Çà¿­ ¹é½Å ½ÃÀå
Bovine Ephemeral Fever Vaccines
»óǰÄÚµå : 1797199
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 377 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,245,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,736,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼ÒÀ¯Çà¿­ ¹é½Å ¼¼°è ½ÃÀåÀº 2030³â±îÁö 8,280¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 7,480¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼ÒÀ¯Çà¿­ ¹é½Å ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 1.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 8,280¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ »ý¹é½ÅÀº CAGR 1.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 4,410¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »ç¹é½Å ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 2.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2,040¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 3.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¼ÒÀ¯Çà¿­ ¹é½Å ½ÃÀåÀº 2024³â¿¡ 2,040¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1,530¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 3.4%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 0.6%¿Í 1.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 0.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¼ÒÀ¯Çà¿­ ¹é½Å ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¼ÒÀ¯Çà¿­ ¹é½Å Á¢Á¾ÀÌ °¡ÃàÀÇ °Ç°­°ú ³óÀå ¼öÀÍ¿¡ Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

BEF(Bovine Ephemeral Fever)´Â ÀϹÝÀûÀ¸·Î »ïÀϺ´À¸·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ƯÈ÷ ¿­´ë ¹× ¾Æ¿­´ë Áö¿ª¿¡¼­ °¡ÃàÀÇ °Ç°­¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡´Â ¹ÙÀÌ·¯½º¼º ÁúȯÀÔ´Ï´Ù. °©ÀÛ½º·± ¹ß¿­, °æÁ÷, ÆÄÇà, ½Ä¿åºÎÁøÀÌ Æ¯Â¡À̸ç, º¸Åë ¼öÀÏ ³»¿¡ ȸº¹µÇÁö¸¸ À¯·® °¨¼Ò, üÁß °¨¼Ò, ÀϽÃÀûÀÎ ºÒÀÓ, ¼öÀÇ»ç ºñ¿ë Áõ°¡·Î ÀÎÇØ ½É°¢ÇÑ °æÁ¦Àû ¼Õ½ÇÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. °æ¿ì¿¡ µû¶ó¼­´Â ÇÕº´ÁõÀ¸·Î »ç¸ÁÇÏ´Â °æ¿ìµµ ÀÖ¾î Æ¯È÷ ³ë·ÉÀÇ µ¿¹°À̳ª »óó¹Þ±â ½¬¿î µ¿¹°ÀÇ °æ¿ì ÁÖÀǰ¡ ÇÊ¿äÇÕ´Ï´Ù. ¹é½Å Á¢Á¾Àº BEF¿¡ ´ëÇÑ °¡Àå È¿°úÀûÀÎ ¿¹¹æ Àü·«À¸·Î µîÀåÇÏ¿© Àüü °¡ÃàÀ» º¸È£ÇÏ°í »ý»ê¼ºÀÇ Áß´ÜÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. ÀÌ Áúº´Àº ¸ð±â, ÆÄ¸® µî ¸Å°³ °ïÃæ¿¡ ÀÇÇØ ¸Å°³µÇ±â ¶§¹®¿¡ °èÀýÀû, Áö¿ªÀû ¹ß»ýÀ» ¿¹ÃøÇϱ⠾î·Á¿ì¸ç, À¯Çà Áö¿ª¿¡¼­´Â ¹é½Å Á¢Á¾ÀÌ ÇʼöÀûÀÔ´Ï´Ù. °¨¿°Áö¿ª Ãà»ê³ó°¡µéÀº °¡ÃàÀÇ °Ç°­À» Áö۰í À°·ù ¹× À¯Á¦Ç° »ý»êÀ¸·Î ¾ÈÁ¤ÀûÀÎ ¼öÀÔÀ» È®º¸Çϱâ À§ÇØ ¼±Á¦Àû ¿¹¹æÁ¢Á¾ÀÇ Á߿伺À» ÀνÄÇϰí ÀÖ½À´Ï´Ù. Àμö°øÅëÀü¿°º´°ú ±× °æÁ¦Àû ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½Ä·® ¾Èº¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 µ¿¹° ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ÀÇ ½Ã±Þ¼ºÀÌ ´õ¿í ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. ¼ÒÀ¯Çà¿­ ¹é½ÅÀº ¾àµ¶¼º »ý¹é½ÅÀÌµç ºÒȰ¼ºÈ­ ¹é½ÅÀ̵ç Áúº´ ¹ß»ýÀ» ¾ïÁ¦Çϰí Àüü ¿ì±ºÀÇ È¸º¹·ÂÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀÎ ¼ö´ÜÀ» Á¦°øÇÕ´Ï´Ù. ³ó¹ýÀÌ Çö´ëÈ­µÇ°í »ó¾÷Àû Ãà»ê¾÷ÀÌ Àü ¼¼°èÀûÀ¸·Î È®´ëµÊ¿¡ µû¶ó ¹é½Å Á¢Á¾Àº Áúº´ °ü¸®¿Í Ãà»ê °æ¿µ °èȹÀÇ ÇʼöÀûÀÎ ºÎºÐÀ¸·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

¹é½Å °³¹ßÀÇ ÁøÀüÀº ¼ÒÀ¯Çà¿­¿¡ ´ëÇÑ ¹æ¾î¸¦ ¾î¶»°Ô °­È­Çϰí Àִ°¡?

ÃÖ±Ù ¹é½Å ±â¼úÀÇ Çõ½ÅÀ¸·Î ¹é½ÅÀÇ À¯È¿¼º, ¾ÈÀü¼º, º¸Á¸¼ºÀÌ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ±âÁ¸¿¡´Â ¾àµ¶¼º »ý¹é½ÅÀÌ ³Î¸® »ç¿ëµÇ¾î °­·ÂÇÑ ¸é¿ª¹ÝÀÀÀ» °¡Á®¿ÔÁö¸¸, ¾ÈÁ¤¼º°ú ¸é¿ª°áÇÌ µ¿¹°ÀÇ À§Çè¿¡ ´ëÇÑ ¿ì·Á°¡ Á¦±âµÇ±âµµ Çß½À´Ï´Ù. ºñȰ¼ºÈ­ ¹ÙÀÌ·¯½º Á¦Á¦ ¹× ¼­ºêÀ¯´Ö ±â¹Ý ¿É¼ÇÀ» Æ÷ÇÔÇÑ Â÷¼¼´ë ¹é½ÅÀº ºÎÀÛ¿ëÀÌ ÀûÀº ¾ÈÀüÇÑ ´ëü ¹é½ÅÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Á¦´Â ¿î¼Û ¹× ÄݵåüÀÎ ¹°·ù°¡ ¾î·Á¿î Áö¿ª¿¡¼­ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ºÐÀÚ»ý¹°ÇÐÀû ¿¬±¸¸¦ ÅëÇØ BEF ¹ÙÀÌ·¯½ºÀÇ ±¸Á¶¿Í Ç׿ø¼º ¼ººÐ¿¡ ´ëÇÑ ÀÌÇØ°¡ ±í¾îÁö¸é¼­ Ç¥ÀûÈ­µÈ ¹é½Å ¼³°è¿Í Áø´Ü ÀûÇÕ¼º Çâ»óÀ» À§ÇÑ ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ÀϺΠÁ¦Á¶¾÷üµéÀº »ì¾ÆÀÖ´Â ¹ÙÀÌ·¯½º¸¦ »ç¿ëÇÏÁö ¾Ê°í Ç׿øÀ» »ý»êÇÏ´Â ÀçÁ¶ÇÕ DNA ±â¼úÀ» ¿¬±¸Çϰí ÀÖÀ¸¸ç, À̸¦ ÅëÇØ »ý¹°ÇÐÀû ¾ÈÀü ±âÁØÀ» °³¼±ÇÏ°í ¹ßº´¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â ºü¸¥ »ý»ê Áֱ⸦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º¸Á¶Á¦ ±â¼úµµ ÁøÈ­ÇÏ¿© ¸é¿ª ¹ÝÀÀÀ» ³ôÀÌ°í ¹æ¾î ±â°£À» ¿¬ÀåÇÏ¿© ÀæÀº ÀçÁ¢Á¾ÀÇ Çʿ伺À» ÁÙ¿©ÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇÑ ¹øÀÇ Á¢Á¾À¸·Î ¿©·¯ ¼ÒÀÇ º´¿øÃ¼¸¦ ¿¹¹æÇÏ´Â ´Ù°¡¹é½Å¿¡ ´ëÇÑ ¿¬±¸µµ ÁøÇà ÁßÀ¸·Î, Æí¸®¼º°ú Æø³ÐÀº Áúº´ ´ë»óÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀ¸·Î BEF ¹é½ÅÀº ´Ù¾çÇÑ ±âÈÄ¿Í °æÀÛ Á¶°Ç¿¡ ÀûÀÀÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, Àü ¼¼°è°¡ ±¸Á¦¿ªÀ» º¸´Ù È¿°úÀûÀ¸·Î ÅëÁ¦Çϱâ À§ÇÑ ³ë·ÂÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ ºÐ¼®, µðÁöÅÐ °Ç°­ ¸ð´ÏÅ͸µ, ¼öÀÇÇÐ ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼ÇÀÇ ÅëÇÕÀº ¿¹¹æÁ¢Á¾ ÀÏÁ¤°ú ¼øÀÀµµ¸¦ ´õ¿í °³¼±ÇÏ°í ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÇ Àü¹ÝÀûÀÎ È¿°ú¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

¼¼°è BEF ¹é½Å ¼ö¿ä¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Áö¿ªÀû, ȯ°æÀû ¿äÀÎÀº?

¼ÒÀ¯Çà¿­ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä´Â ±âÈÄ, ¼ÒÀÇ Àα¸¹Ðµµ, ³ó¹ý, Áúº´ À¯Çà µîÀÇ Â÷ÀÌ·Î ÀÎÇØ Áö¿ª¸¶´Ù Å©°Ô ´Ù¸¨´Ï´Ù. BEF´Â ¾Æ½Ã¾Æ, ¾ÆÇÁ¸®Ä«, È£ÁÖ, Áßµ¿ ÀϺΠÁö¿ª¿¡¼­ °¡Àå À¯ÇàÇϰí ÀÖÀ¸¸ç, µû¶æÇÏ°í ½Àµµ°¡ ³ô°í ¹ÙÀÌ·¯½º ¸Å°³ °ïÃæ º¤ÅÍ¿¡ ÀÌ»óÀûÀÎ Á¶°ÇÀ» °®Ãß°í ÀÖ½À´Ï´Ù. È£ÁÖ¿¡¼­ BEF´Â ¿ª»çÀûÀ¸·Î ºÏºÎ¿Í µ¿ºÎ¿¡¼­ ¸¹ÀÌ ¹ß»ýÇßÀ¸¸ç, ÀÌ¿¡ µû¶ó °ø°ø ¹× ¹Î°£ ¼öÀÇÇÐ ¼­ºñ½º¸¦ ÅëÇÑ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ÀÌ ³Î¸® ÆÛÁ® ÀÖ½À´Ï´Ù. Àεµ³×½Ã¾Æ, ű¹, Çʸ®ÇÉ µî µ¿³²¾Æ½Ã¾Æ ±¹°¡¿¡¼­µµ °èÀýÀû À¯ÇàÀÌ º¸°íµÇ°í ÀÖÀ¸¸ç, Á¤ºÎ ÁÖµµÀÇ ÀÎ½Ä °³¼± Ä·ÆäÀΰú ¹é½Å Á¢Á¾¿¡ ´ëÇÑ º¸Á¶±ÝÀ» Áö±ÞÇϰí ÀÖ½À´Ï´Ù. Ãà»ê¾÷ÀÌ ÁÖ¿ä »ý°è ¼ö´ÜÀÎ ¾ÆÇÁ¸®Ä«¿¡¼­´Â BEF°¡ »ê¹ßÀûÀ̱ä ÇÏÁö¸¸ ½É°¢ÇÏ°Ô À¯ÇàÇϰí ÀÖÀ¸¸ç, ³óÃÌ Áö¿ª ³óºÎµéÀº À¯Åë ¹®Á¦¿Í Á¦ÇÑµÈ ÀÎÇÁ¶ó·Î ÀÎÇØ ¹é½Å Á¢±Ù¿¡ ¾î·Á¿òÀ» °Þ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. »ç¿ìµð¾Æ¶óºñ¾Æ¿Í À̶õÀ» Æ÷ÇÔÇÑ Áßµ¿ ±¹°¡µéÀº ±âÈĺ¯È­·Î ÀÎÇÑ Áúº´ ¾Ð·Â¿¡ Ãë¾àÇÑ ¼ºÀå ÁßÀÎ ³«³ó ¹× À°¿ì ºÎ¹®À» º¸È£Çϱâ À§ÇØ BEF ¹é½Å Á¢Á¾¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿¡¼­´Â ÀÌ Áúº´ÀÇ À¯ÇàÀº ÀûÁö¸¸, ±¹°æÀ» ³Ñ´Â µ¿¹° Áúº´¿¡ ´ëÇÑ ¿ì·Á°¡ ³ô¾ÆÁü¿¡ µû¶ó BEF¸¦ º¸´Ù ±¤¹üÀ§ÇÑ µ¿¹° À§»ý °¨½Ã ½Ã½ºÅÛ¿¡ ÅëÇÕÇÏ´Â °ÍÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ±â¿Â »ó½Â°ú °­¼ö ÆÐÅÏÀÇ º¯È­¿Í °°Àº ȯ°æ º¯È­´Â °ïÃæ ¸Å°³ µ¿¹°ÀÇ Áö¸®Àû ¹üÀ§¸¦ È®ÀåÇϰí BEF¸¦ »õ·Î¿î Áö¿ªÀ¸·Î °¡Á®¿Ã ¼ö ÀÖÀ¸¸ç, ÀÌÀü¿¡´Â ¿µÇâÀ» ¹ÞÁö ¾Ê¾Ò´ø Áö¿ª¿¡¼­ÀÇ ¿¹¹æ ¹é½Å Á¢Á¾À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °¡Ãà À§»ý ±ÔÁ¦°¡ ¾ö°ÝÇÑ ±¹°¡µéÀº ±¹°æÀ» ³Ñ¾î ¼Ò¸¦ À̵¿½Ãų ¶§ ¹é½Å Á¢Á¾ Áõ¸í¼­¸¦ ¿ä±¸Çϰí ÀÖÀ¸¸ç, ¼öÃâ ÁöÇâÀûÀÎ ³ó¾÷ °æÁ¦±Ç¿¡¼­ ¹é½Å Á¢Á¾À» ´õ¿í Àå·ÁÇϰí ÀÖ½À´Ï´Ù.

¼¼°è ¼ÒÀ¯Çà¿­ ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼ÒÀ¯Çà¿­ ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀº Áúº´ÀÇ È®»ê, °¡Ãà ¼öÀÇ Áõ°¡, ¹é½Å Á¦Á¦ÀÇ ¹ßÀü, ¼öÀÇÇÐ ÀÎÇÁ¶óÀÇ È®Àå µîÀÇ º¹ÇÕÀûÀÎ ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â BEF ¹ß»ý¿¡ µû¸¥ °æÁ¦Àû À§Çè, ƯÈ÷ À¯·® °¨¼Ò, ¹ø½Ä·Â ÀúÇÏ, Ä¡·áºñ Áõ°¡¿¡ ´ëÇÑ ³ó°¡¿Í Ãà»ê³ó°¡ÀÇ ÀνÄÀÌ ³ô¾ÆÁ³´Ù´Â Á¡ÀÔ´Ï´Ù. À°·ù ¹× À¯Á¦Ç°¿¡ ´ëÇÑ Àü ¼¼°è ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó »ý»êÀÚµéÀº °Ç°­ÇÏ°í »ý»êÀûÀÎ °¡ÃàÀ» À¯ÁöÇØ¾ß Çϸç, Áúº´ ¿¹¹æÀ» ÃÖ¿ì¼± °úÁ¦·Î »ï°í ÀÖ½À´Ï´Ù. Á¤ºÎ Á¤Ã¥°ú ¼öÀǺ¸°Ç ÇÁ·Î±×·¥µµ º¸Á¶±Ý, ÀÎ½Ä °³¼± Ä·ÆäÀÎ, °íÀ§Çè Áö¿ª¿¡¼­ÀÇ ¿¹¹æÁ¢Á¾ Àǹ«È­ µîÀ» ÅëÇØ ¹é½Å Á¢Á¾À» ÃËÁøÇÏ´Â µî ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¾ÆÇÁ¸®Ä« ÀϺΠÁö¿ª¿¡¼­´Â »ó¾÷Àû Ãà»ê¾÷ÀÌ È®´ëµÇ°í ÄݵåüÀÎ ¹°·ù ¹× À¯Åë¸ÁÀÌ °³¼±µÇ¸é¼­ µ¿¹°¿ë ¹é½Å ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. 1ȸ Åõ¿© ¿ä¹ýÀ̳ª ³»¿­¼º Á¦Çü°ú °°Àº ¹é½Å °ø±ÞÀÇ Çõ½ÅÀº ³«³ó°¡µéÀÇ Á¢±Ù¼º ¹× ±ÔÁ¤ Áؼö¸¦ ´õ¿í Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µ¿¹° À§»ý µ¥ÀÌÅÍ ½Ã½ºÅÛÀÇ ÅëÇÕÀÌ ÁøÇàµÊ¿¡ µû¶ó º¸´Ù Á¤È®ÇÑ Áúº´ ÃßÀû, Á¶±â °æº¸ ¾Ë¸², Àü·«Àû ¹é½Å ¹èÄ¡°¡ °¡´ÉÇØÁ³½À´Ï´Ù. µ¿¹° »ý¸í°øÇп¡ ´ëÇÑ ¹Î°£ ºÎ¹®ÀÇ ÅõÀÚ¿Í ¼öÀÇÇÐ °Ç°­ °ü·Ã ±¹Á¦ °øµ¿ ¿¬±¸´Â º¸´Ù °æÀïÀûÀ̰í Çõ½ÅÀûÀÎ ½ÃÀå ȯ°æ¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î ¼ÒÀ¯Çà¿­ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°è °¡Ãà À§»ý °ü¸® ¹× ³ó¾÷ »ý»ê¼º Çâ»ó¿¡ Áß¿äÇÑ ¿ä¼Ò·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(»ý¹é½Å, »ç¹é½Å, ±âŸ À¯Çü), ¿ëµµ(¼Ò¿ë, ¹°¼Ò¿ë), ÃÖÁ¾»ç¿ëÀÚ(ÀÇ·á±â±â ±â¾÷, Á¦¾à, µ¿¹° º´¿ø, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Bovine Ephemeral Fever Vaccines Market to Reach US$82.8 Million by 2030

The global market for Bovine Ephemeral Fever Vaccines estimated at US$74.8 Million in the year 2024, is expected to reach US$82.8 Million by 2030, growing at a CAGR of 1.7% over the analysis period 2024-2030. Live Vaccine, one of the segments analyzed in the report, is expected to record a 1.4% CAGR and reach US$44.1 Million by the end of the analysis period. Growth in the Killed Vaccine segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$20.4 Million While China is Forecast to Grow at 3.4% CAGR

The Bovine Ephemeral Fever Vaccines market in the U.S. is estimated at US$20.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$15.3 Million by the year 2030 trailing a CAGR of 3.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.8% CAGR.

Global Bovine Ephemeral Fever Vaccines Market - Key Trends & Drivers Summarized

Why Is Bovine Ephemeral Fever Vaccination Critical for Livestock Health and Farm Profitability?

Bovine ephemeral fever (BEF), commonly known as three-day sickness, is a viral disease that significantly impacts cattle health, particularly in tropical and subtropical regions. Characterized by sudden fever, stiffness, lameness, and loss of appetite, the disease typically resolves within a few days but can lead to severe economic losses due to reduced milk production, weight loss, temporary infertility, and increased veterinary costs. In some cases, complications can even result in death, especially in older or more vulnerable animals. Vaccination has emerged as the most effective preventive strategy against BEF, offering protection to entire herds and minimizing productivity disruptions. Given that the disease is transmitted by biting insects such as mosquitoes and midges, its seasonal and regional outbreaks can be hard to predict, making vaccination essential in endemic zones. Livestock farmers in affected areas are increasingly recognizing the importance of preemptive immunization to safeguard herd health and ensure stable income from meat and dairy production. The rising demand for food security, along with growing awareness of zoonotic diseases and their economic implications, further highlights the urgency for robust animal vaccination programs. Bovine ephemeral fever vaccines, whether live attenuated or inactivated, provide a cost-effective tool for reducing disease incidence and improving overall herd resilience. As farming practices modernize and commercial livestock production scales up globally, vaccination is becoming an integral part of disease management and operational planning for cattle-rearing operations.

How Are Advancements in Vaccine Development Enhancing Protection Against Bovine Ephemeral Fever?

Recent innovations in vaccine technology are significantly improving the efficacy, safety, and shelf-life of bovine ephemeral fever vaccines. Traditionally, live attenuated vaccines were widely used, offering strong immune responses but sometimes raising concerns about stability and risk in immunocompromised animals. New-generation vaccines, including inactivated virus formulations and subunit-based options, are addressing these challenges by providing safer alternatives with minimal side effects. These formulations are particularly valuable in regions where transportation and cold-chain logistics are difficult, as advancements in thermostable vaccines reduce the need for constant refrigeration. Molecular research has also led to a better understanding of the BEF virus structure and antigenic components, paving the way for targeted vaccine design and improved diagnostic compatibility. Some manufacturers are exploring recombinant DNA techniques to produce antigens without using the live virus, thereby improving biosafety standards and enabling faster production cycles in response to outbreaks. Additionally, adjuvant technologies have evolved to enhance the immune response and prolong the duration of protection, reducing the need for frequent re-vaccinations. Research into multivalent vaccines that protect against multiple bovine pathogens in a single dose is also gaining ground, offering convenience and broader disease coverage. These technological strides are making BEF vaccines more adaptable to varied climatic and farming conditions, supporting global efforts to control vector-borne cattle diseases more effectively. The integration of data analytics, digital health monitoring, and veterinary mobile applications is further improving vaccination schedules and compliance rates, enhancing the overall impact of immunization programs.

What Regional and Environmental Factors Influence the Demand for BEF Vaccines Worldwide?

The demand for bovine ephemeral fever vaccines varies significantly across regions due to differences in climate, cattle population density, farming practices, and disease prevalence. BEF is most prevalent in parts of Asia, Africa, Australia, and the Middle East, where warm temperatures and high humidity provide ideal conditions for the insect vectors that transmit the virus. In Australia, BEF outbreaks have been historically common in the northern and eastern regions, leading to widespread vaccination programs supported by both public and private veterinary services. Southeast Asian nations like Indonesia, Thailand, and the Philippines also report seasonal outbreaks, prompting government-led awareness campaigns and subsidies for vaccine access. In Africa, where livestock farming is a major livelihood, BEF outbreaks are sporadic but severe, with rural farmers often struggling to access vaccines due to distribution challenges and limited infrastructure. Middle Eastern countries, including Saudi Arabia and Iran, have increased their focus on BEF vaccination to protect growing dairy and beef sectors that are vulnerable to climate-induced disease pressures. In Latin America, the disease is less prevalent but growing concerns about transboundary animal diseases have prompted inclusion of BEF in broader animal health surveillance systems. Environmental changes, including rising temperatures and altered precipitation patterns, are expanding the geographical range of insect vectors, potentially introducing BEF into new regions and prompting preventive vaccination in previously unaffected areas. Regional trade dynamics also influence vaccine demand, as countries with strict livestock health regulations require vaccination certificates for cross-border cattle movements, further incentivizing vaccination uptake in export-oriented farming economies.

What Are the Main Factors Driving the Growth of the Bovine Ephemeral Fever Vaccines Market Globally?

The growth in the bovine ephemeral fever vaccines market is driven by a combination of rising disease prevalence, increasing livestock populations, advancements in vaccine formulation, and expanding veterinary infrastructure. One of the primary factors is the growing awareness among farmers and livestock producers about the economic risks associated with BEF outbreaks, particularly in terms of lost milk yield, reduced fertility, and higher treatment costs. As the global demand for meat and dairy products continues to rise, producers are under increasing pressure to maintain healthy and productive herds, making disease prevention a top priority. Government policies and veterinary health programs are also playing a pivotal role by promoting vaccination through subsidies, awareness campaigns, and mandatory immunization initiatives in high-risk areas. The expansion of commercial livestock farming, especially in Asia-Pacific and parts of Africa, has created a larger market for animal vaccines, supported by better cold-chain logistics and distribution networks. Innovations in vaccine delivery, such as single-dose regimens and thermostable formulations, are further enhancing accessibility and compliance among farmers. In addition, the growing integration of animal health data systems allows for more accurate disease tracking, early warning alerts, and strategic vaccine deployment. Private sector investment in animal biotechnology and international collaborations on veterinary health research are contributing to a more competitive and innovative market landscape. Collectively, these factors are fueling a sustained increase in demand for bovine ephemeral fever vaccines, positioning them as a critical component of global livestock health management and agricultural productivity enhancement.

SCOPE OF STUDY:

The report analyzes the Bovine Ephemeral Fever Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Live Vaccine, Killed Vaccine, Other Types); Application (Cattle Application, Water Buffaloes Application); End-User (Medical Device Companies End-User, Pharmaceutical End-User, Animal Hospitals End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â